Le Registre des lobbyistes
Objets | Détails | Catégories |
---|---|---|
Développement international,
Propriété intellectuelle,
Santé
|
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP).
|
Politique ou Programme
|
Budget,
Impôts et finances
|
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.
|
Politique ou Programme
|
Santé
|
Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs.
|
Politique ou Programme
|
Commerce international,
Développement international,
Propriété intellectuelle
|
Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
|
Politique ou Programme
|
Recherche et développement,
Santé
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
|
Politique ou Programme
|
Environnement,
Recherche et développement
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
|
Proposition législative, Projet de loi ou résolution,
Règlement
|
Recherche et développement,
Santé
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiatives as it relates to public/private research and development partnerships and to the Drug Safety and Effective Network (DSEN).
|
Politique ou Programme
|
Recherche et développement
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.
|
Politique ou Programme
|
Industrie,
Santé,
Sciences et technologies
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).
|
Politique ou Programme
|
Recherche et développement,
Santé
|
Federal Government involvement in national strategies to address major chronic diseases having a significant burden on the Canadian health care system, such as Dementia, Diabetes, Hepatitis C and Cancer and major public health concerns such as Antimicrobial resistant.
|
Politique ou Programme
|
Sécurité nationale/sécurité,
Vie privée et Accès à l'information
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.
|
Règlement
|
Affaires étrangères,
Commerce international,
Développement international
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.
|
Proposition législative, Projet de loi ou résolution,
Règlement
|
Santé
|
Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.
|
Politique ou Programme
|
Impôts et finances
|
Income Tax Act as it relates to biopharmaceutical products.
|
Proposition législative, Projet de loi ou résolution
|
Relations fédérales-provinciales,
Santé
|
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.
|
Politique ou Programme
|
Recherche et développement,
Santé
|
New Substances Notification Regulations as it relates to the biopharmaceutical industry.
|
Règlement
|
Affaires étrangères,
Développement international,
Santé
|
Partnership opportunities as it relates to Canada's policy and programs to improve health in the developing world, such as Maternal and Child Health.
|
Politique ou Programme
|
Propriété intellectuelle
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.
|
Proposition législative, Projet de loi ou résolution
|
Propriété intellectuelle
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products.
|
Règlement
|
Commerce international,
Propriété intellectuelle
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.
|
Règlement
|
Propriété intellectuelle,
Sciences et technologies
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.
|
Règlement
|
Propriété intellectuelle,
Recherche et développement
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
|
Politique ou Programme
|
Commerce intérieur,
Questions touchant les consommateurs
|
Plan design and reimbursement policies for drug plans administered by Federal Government including NIHB and Corrections Services.
|
Politique ou Programme
|
Questions touchant les consommateurs,
Recherche et développement,
Santé
|
Policies and programs as it relates to vaccine approval, procurement and public awareness of immunization.
|
Politique ou Programme
|
Impôts et finances
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits.
|
Politique ou Programme
|
Industrie,
Santé
|
Smart Regulations as it relates to the biopharmaceutical industry.
|
Règlement
|
Propriété intellectuelle,
Santé
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations.
|
Politique ou Programme
|
Sciences et technologies
|
The government's Science and Technology strategy as it relates to the biopharmaceutical industry.
|
Politique ou Programme
|
Commerce international,
Développement international
|
US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.
|
Politique ou Programme
|
Santé,
Sécurité nationale/sécurité
|
World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG).
|
Politique ou Programme
|
Objets | Détails | Catégories |
---|---|---|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP).
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.
|
Proposition législative, Projet de loi ou résolution
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
|
Proposition législative, Projet de loi ou résolution,
Règlement
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiatives as it relates to public/private research and development partnerships and to the Drug Safety and Effective Network (DSEN).
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Federal Government involvement in national strategies to address major chronic diseases having a significant burden on the Canadian health care system, such as Dementia, Diabetes, Hepatitis C and Cancer and major public health concerns such as Antimicrobial resistant.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.
|
Règlement
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.
|
Proposition législative, Projet de loi ou résolution,
Règlement
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Income Tax Act as it relates to biopharmaceutical products.
|
Proposition législative, Projet de loi ou résolution
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
New Substances Notification Regulations as it relates to the biopharmaceutical industry.
|
Règlement
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Partnership opportunities as it relates to Canada's policy and programs to improve health in the developing world, such as Maternal and Child Health.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.
|
Proposition législative, Projet de loi ou résolution
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products.
|
Règlement
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.
|
Règlement
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.
|
Règlement
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Plan design and reimbursement policies for drug plans administered by Federal Government including NIHB and Corrections Services.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Policies and programs as it relates to vaccine approval, procurement and public awareness of immunization.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Smart Regulations as it relates to the biopharmaceutical industry.
|
Règlement
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
The government's Science and Technology strategy as it relates to the biopharmaceutical industry.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.
|
Politique ou Programme
|
Il n'était pas requis d'associer l'objet aux détails sur l'objet lors de la soumission de cet enregistrement
|
World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG).
|
Politique ou Programme
|
Techniques de communication déjà utilisées ou qui seront utilisées au cours de l'engagement :
Date | TCPD, Titre du poste | Institution gouvernementale | Objets |
---|---|---|
2024-05-25 |
|
Santé, Industrie, Recherche et développement |
2024-05-24 |
|
Santé, Industrie, Recherche et développement |
2024-05-23 |
|
Santé, Industrie, Recherche et développement |
2024-05-22 |
|
Santé, Industrie, Recherche et développement |
2024-04-04 |
|
Industrie, Recherche et développement |
2024-02-15 |
|
Industrie, Recherche et développement, Sciences et technologies |
2023-11-08 |
|
Santé, Industrie |
2023-11-08 |
|
Santé, Industrie, Développement économique |
2023-11-07 |
|
Santé, Industrie |
2023-11-06 |
|
Santé |
2023-10-11 |
|
Santé, Industrie |
2023-09-22 |
|
Santé, Industrie |
2023-09-05 |
|
Santé, Développement économique, Recherche et développement |